MBI and Shionogi to cancel agreement

Article

Ultrasound contrast agent developer Molecular Biosystems of SanDiego announced last week that it has exchanged breach-of-contractnotices with its Japanese licensee, Shionogi & Co. of Osaka.MBI said that the two companies have been unable to agree on

Ultrasound contrast agent developer Molecular Biosystems of San

Diego announced last week that it has exchanged breach-of-contract

notices with its Japanese licensee, Shionogi & Co. of Osaka.

MBI said that the two companies have been unable to agree on terms

for canceling their relationship, which covers distribution of

MBI's Albunex agent in Japan, Taiwan, and South Korea. MBI claims

that Shionogi has not diligently pursued the development and distribution

of Albunex in its territory, while Shionogi claims that MBI supplied

it with batches of Albunex that fail to meet adequate quality

standards. MBI said that it will pursue another licensee for Albunex

in the territory.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.